FDA Cleared Advantage AHI System is FDA-cleared clinical decision support that predicts hemodynamic instability with lead times, offering hospitals a regulatory-validated path to intervene earlier, reduce crises, and improve patient throughput.

Easy Adoption The system runs on a single noninvasive ECG lead II with no manual inputs and no new hardware, enabling rapid deployment across telemetry units and fast time-to-value for clinical teams.

Integration Potential Recent partnerships with Sickbay, AirStrip, and Qualio demonstrate strong integration readiness with existing hospital IT, analytics, and interoperability platforms, positioning Fifth Eye for channel partnerships with EMR and monitoring vendors.

Target Market Ideal buyers are hospitals and health systems using continuous ECG monitoring; messaging should emphasize cost savings from preventing instability crises, improved patient throughput, and shorter lengths of stay.

Growth Path As a venture-backed, small team with strategic partnerships and industry recognition as a top AI solutions provider, Fifth Eye can pursue pilots and co-development deals with regional to national healthcare networks, leveraging partner ecosystems to scale.